consortium in 2019. Since that time, the Lab Owl product has been integrated into ARMI’s Tissue Foundry manufacturing process, and the Lab Owl team has made important contributions to several working groups tasked with solving some of the challenges facing tissue engineering and regenerative medicine manufacturing. These working groups include establishing ARMI’s Workforce Characteristics Charter; the Tissue Maturation and Bioreactor Charter; and the Cell Culture and Harvest Charter.
Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.